R&D News | pharmaphorum

News

Dicerna agrees another gene-silencing deal, this time with L...

Eli Lilly has agreed a broad collaboration with Dicerna, sealing the deal with a $100 million equity stake in the RNA interference specialist.

News

Pfizer and Novartis collaborate to find liver disease therap...

Pfizer has joined forces with Novartis to bring together the therapies they have been working on independently, to treat non-alcoholic steatohepatitis (NASH).

News

Zytiga generics looming as US court nixes J&J patent

Johnson & Johnson has lost another round in its patent defence for prostate cancer blockbuster Zytiga, raising the possibility that generics could launch in the coming days.

News

Takeda proposes selling Shire’s IBD treatment after merger

Takeda has proposed selling off a Shire treatment for inflammatory bowel disease when the companies merge next year, to avoid an overlap with its own drug.

News

Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms.

Magic mushroom drug could be depression breakthrough, says F...

The liberty cap mushroom, notoriously used illegally as a psychoactive drug, could be the inspiration for a new therapy for depression according to the US drug regulator.

News

Lundbeck craters as resistant schizophrenia drug fails phase...

Danish drugmaker Lundbeck saw more than a quarter of the value wiped off its shares yesterday after its top pipeline prospect, a drug for schizophrenia, missed the mark in a phase III trial.

Dicerna agrees another gene-silencing deal, this time with L...

Pfizer and Novartis collaborate to find liver disease therap...

Zytiga generics looming as US court nixes J&J patent

Takeda proposes selling Shire’s IBD treatment after merger

Magic mushroom drug could be depression breakthrough, says F...

Lundbeck craters as resistant schizophrenia drug fails phase...

Obesity needs a new clinical definition, study finds

Securing your ROI: Turning post-acquisition integration into...

News

Editor's Picks